A study of pharmacokinetic of rifapentine combined with isoniazid in the preventive treatment of tuberculosis in silicotic patients

doi:10.3969/j.issn.1000-6621.2021.03.007

Abstract

Abstract:

Objective To evaluate the pharmacokinetic characteristics of rifapentine combined with isoniazid therapy (3HP for 3 months, once a week) for tuberculosis prevention in silicotic patients. Methods A total of 25 silicosis patients treated with 3HP regimen and pharmacokinetic monitoring in the First People's Hospital of Wenling City, Zhejiang Province from May 2015 to June 2018 were selected as the research subjects. At 8 weeks after the initiation of treatment, before taking the drug, the patients should stayed overnight (more than 10 h) without any food, peripheral venous blood was collected in limosis the next morning (0 h before taking the drug), and at 2, 4, 5, 6, 8, 12, 24, and 72 h after taking the drug. The plasma concentrations of isoniazid, rifapentine and their metabolites were determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Pharmacokinetic parameters were obtained by analyzing the plasma concentration data using DAS 2.0 software. Results The pharmacokinetic parameters (M (Q₁, Q₃)) of isoniazid and theacetyl metabolite were as follows: AUC_(0-_t₎, 14.1 (10.3, 22.2) and 7.6 (6.3, 8.4) μg·h/ml; AUC_(0-∞), 14.3 (10.7, 22.4) and 8.0 (7.2, 9.2) μg·h/ml; t_1/2, 1.6 (1.3, 1.8) and 6.0 (5.2, 7.9) h; t_max, 2.0 (2.0, 4.0) and 2.0 (2.0, 4.5) h; C_max, 3.7 (2.4, 5.5) and 6.6 (5.5, 9.8) μg/ml. And the main pharmacokinetic parameters (M (Q₁, Q₃)) of rifapentine and the active 25-desacetyl metabolite were as follows: AUC_(0-_t₎, 919.6 (742.3, 1113.1) and 660.1 (517.6, 739.8) μg·h/ml; AUC_(0-∞), 1035.4 (758.2, 1191.3) and 913.4 (685.7, 1097.3) μg·h/ml; t_1/2, 18.3 (14.5, 21.6) and 32.3 (22.1, 46.3) h; t_max, 8.0 (7.0, 12.0) and 24.0 (18.0, 24.0) h; C_max, 32.2 (28.6, 37.7) and 15.1 (11.2, 18.2) μg/ml. All the subjects were followed up until 1 month after the completion of medication, of them, 14 cases (56.0%) had adverse drug reactions. Conclusion When the 3HP regimen was applied to prevent tuberculosis in silicotic patients, the metabolism of isoniazid was faster, while the metabolism of rifapentin was slower, which may be related to the occurrence of more adverse drug reactions in patients.

Key words: Tuberculosis, Protective agents, Rifamycins, Isoniazid, Pharmacokinetics

YANG Qing-luan, LIU Qi-hui, LIN Miao-yao, XU Yu-zhen, LIU Xue-feng, HE Zhang-yu-fan, HUANG Xi-tian, HAO Bin, SHAO Ling-yun, ZHANG Wen-hong, RUAN Qiao-ling. A study of pharmacokinetic of rifapentine combined with isoniazid in the preventive treatment of tuberculosis in silicotic patients[J]. Chinese Journal of Antituberculosis, 2021, 43(3): 228-232. doi: 10.3969/j.issn.1000-6621.2021.03.007

Figures/Tables 1

References 22

[1]	World Health Organization. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva: World Health Organization, 2018.
[2]	Ruan Q, Huang X, Yang Q, et al. Efficacy and safety of weekly rifapentine and isoniazid for tuberculosis prevention in Chinese silicosis patients: a randomized controlled trial. [J/OL]. Clin Microbiol Infect, 2020[2021-01-26]. doi: 10.1016/j.cmi.2020.06.008.Online ahead of print.
[3]	Winchester L, Podany A, Baldwin JS, et al. Determination of the rifamycin antibiotics rifabutin, rifampin, rifapentine and their major metabolites in human plasma via simultaneous extraction coupled with LC/MS/MS. J Pharm Biomed Anal, 2015,104:55-61. doi: 10.1016/j.jpba.2014.11.011. doi: 10.1016/j.jpba.2014.11.011 URL pmid: 25481085
[4]	Ng KY, Zhou H, Zhang YL, et al. Quantification of isoniazid and acetylisoniazid in rat plasma and alveolar macrophages by liquid chromatography-tandem mass spectrometry with on-line extraction. J Chromatogr B Analyt Technol Biomed Life Sci, 2007,847(2):188-198. doi: 10.1016/j.jchromb.2006.10.008. doi: 10.1016/j.jchromb.2006.10.008 URL pmid: 17070115
[5]	Hee KH, Seo JJ, Lee LS. Development and validation of liquid chromatography tandem mass spectrometry method for simultaneous quantification of first line tuberculosis drugs and metabolites in human plasma and its application in clinical study. J Pharm Biomed Anal, 2015,102:253-260. doi: 10.1016/j.jpba.2014.09.019. doi: 10.1016/j.jpba.2014.09.019 URL pmid: 25459921
[6]	Goutal S, Auvity S, Legrand T, et al. Validation of a simple HPLC-UV method for rifampicin determination in plasma: Application to the study of rifampicin arteriovenous concentration gradient. J Pharm Biomed Anal, 2016,123:173-178. doi: 10.1016/j.jpba.2016.02.013. doi: 10.1016/j.jpba.2016.02.013 URL pmid: 26907700
[7]	Lee MR, Huang HL, Lin SW, et al. Isoniazid Concentration and NAT2 Genotype Predict Risk of Systemic Drug Reactions during 3HP for LTBI. J Clin Med, 2019,8(6):812. doi: 10.3390/jcm8060812.
[8]	Brooks KM, George JM, Pau AK, et al. Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug-Drug Interaction Study of Dolutegravir With Once-Weekly Isoniazid and Rifapen-tine. Clin Infect Dis, 2018,67(2):193-201. doi: 10.1093/cid/ciy082. URL pmid: 29415190
[9]	Sterling T, Villarino M, Borisov A, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med, 2011,365(23):2155-2166. doi: 10.1056/NEJMoa1104875. doi: 10.1056/NEJMoa1104875 URL pmid: 22150035
[10]	Sun HY, Huang YW, Huang WC, et al. Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan. Tuberculosis (Edinb), 2018,111:121-126. doi: 10.1016/j.tube.2018.05.013.
[11]	Gao L, Zhang H, Xin H, et al. Short-course regimens of rifapentine plus isoniazid to treat latent tuberculosis infection in older Chinese patients: a randomised controlled study. Eur Respir J, 2018,52(6):1801470. doi: 10.1183/13993003.01470-2018. doi: 10.1183/13993003.01470-2018 URL pmid: 30361241
[12]	Ben Fredj N, Ben Romdhane H, Woillard JB, et al. Pharmacokinetic population of isoniazid in Tunisian tuberculosis patients. Int J Infect Dis, 2021[2021-01-26]. doi: 10.1016/j.ijid.2021.01.033. Online ahead of print. doi: 10.1016/j.ijid.2021.02.083 URL pmid: 33636355
[13]	Weiner M, Burman W, Vernon A, et al. Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am J Respir Crit Care Med, 2003,167(10):1341-1347. doi: 10.1164/rccm.200208-951OC. URL pmid: 12531776
[14]	Savic RM, Lu Y, Bliven-Sizemore E, et al. Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability. Antimicrob Agents Chemother, 2014,58(6):3035-3042. doi: 10.1128/AAC.01918-13. doi: 10.1128/AAC.01918-13 URL pmid: 24614383
[15]	Zurlinden TJ, Eppers GJ, Reisfeld B. Physiologically Based Pharmacokinetic Model of Rifapentine and 25-Desacetyl Rifapentine Disposition in Humans. Antimicrob Agents Chemother, 2016,60(8):4860-4868. doi: 10.1128/AAC.00031-16. doi: 10.1128/AAC.00031-16 URL pmid: 27270284
[16]	Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs, 2014,74(8):839-854. doi: 10.1007/s40265-014-0222-8. doi: 10.1007/s40265-014-0222-8 URL pmid: 24846578
[17]	Weiner M, Bock N, Peloquin CA, et al. Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy. Am J Respir Crit Care Med, 2004,169(11):1191-1197. doi: 10.1164/rccm.200311-1612OC. doi: 10.1164/rccm.200311-1612OC URL pmid: 14962821
[18]	Weiner M, Savic RM, Kenzie WR, et al. Rifapentine Pharmacokinetics and Tolerability in Children and Adults Treated Once Weekly With Rifapentine and Isoniazid for Latent Tuberculosis Infection. J Pediatric Infect Dis Soc, 2014,3(2):132-145. doi: 10.1093/jpids/pit077. doi: 10.1093/jpids/pit077 URL pmid: 26625366
[19]	Egelund EF, Weiner M, Singh RP, et al. Protein binding of rifapentine and its 25-desacetyl metabolite in patients with pulmonary tuberculosis. Antimicrob Agents Chemother, 2014,58(8):4904-4910. doi: 10.1128/AAC.01730-13. doi: 10.1128/AAC.01730-13 URL pmid: 24841270
[20]	Langdon G, Wilkins JJ, Smith PJ, et al. Consecutive-dose pharmacokinetics of rifapentine in patients diagnosed with pulmonary tuberculosis. Int J Tuberc Lung Dis, 2004,8(7):862-867. URL pmid: 15260278
[21]	Choi R, Jeong B, Koh WJ, et al. Recommendations for Optimizing Tuberculosis Treatment: Therapeutic Drug Monitoring, Pharmacogenetics, and Nutritional Status Considerations. Ann Lab Med, 2017,37(2):97-107. doi: 10.3343/alm.2017.37.2.97. doi: 10.3343/alm.2017.37.2.97 URL pmid: 28028995
[22]	Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet, 2009,48(3):143-157. doi: 10.2165/00003088-200948030-00001. doi: 10.2165/00003088-200948030-00001 URL pmid: 19385708

药品及其代谢产物	AUC_(0~_t₎ (μg·h/ml)	AUC_(0~∞) (μg·h/ml)	t_1/2(h)	t_max(h)	C_max (μg/ml)
异烟肼	14.1(10.3,22.2)	14.3(10.7,22.4)	1.6(1.3,1.8)	2.0(2.0,4.0)	3.7(2.4,5.5)
乙酰异烟肼	7.6(6.3,8.4)	8.0(7.2,9.2)	6.0(5.2,7.9)	2.0(2.0,4.5)	6.6(5.5,9.8)
利福喷丁	919.6(742.3,1113.1)	1035.4(758.2,1191.3)	18.3(14.5,21.6)	8.0(7.0,12.0)	32.2(28.6,37.7)
25-去乙酰利福喷丁	660.1(517.6,739.8)	913.4(685.7,1097.3)	32.3(22.1,46.3)	24.0(18.0,24.0)	15.1(11.2,18.2)